Stock prices in London opened mixed on Thursday while European counterparts were in the green, amid news that the UK economy flatlined monthly in June amid investor caution before the general election in July.The FTSE 100 index opened up 8.31 points, or 0.1%, at 8,289.36. The FTSE 250 was down 41.98 points, or 0.2%, at 20,910.54, and the AIM All-Share was down 0.87 points, or 0.1%, at 770.64.The C

Stock prices in the UK, France and Germany were higher at midday Wednesday as investors await a US consumer price inflation print, after UK CPI inflation was reported higher.The FTSE 100 index was up 28.63 points, or 0.4%, at 8,263.86. The FTSE 250 was up 114.24 points, or 0.6%, at 20,858.32, and the AIM All-Share was up 1.10 points, or 0.1%, at 769.08.The Cboe UK 100 was up 0.5% at 826.01, the Cb

Stock prices in London were in the green on Wednesday morning, after Office for National Statistics data showed that while the rise in consumer prices accelerated, it was softer than anticipated.The FTSE 100 index opened 50.47 points, or 0.6%, at 8,285.28. The FTSE 250 was up 129.38 points, 0.6%, at 20,874.28, and the AIM All-Share was up 1.62 points, or 0.2%, at 769.60.The Cboe UK 100 was up 0.8%

Stock prices in London were lower at midday Tuesday, after data showed the UK unemployment rate fell unexpectedly, and ahead of a key inflationary print from the US in the afternoon.The FTSE 100 index was down 20.74 points, or 0.3%, at 8,189.67. The FTSE 250 was down 1.46 points at 20,675.73, and the AIM All-Share was down 0.68 points, or 0.1%, at 766.31.The Cboe UK 100 was down 0.3% at 817.33, th

Wetherspoon chair sells 1% of companyCreightons and hVIVO executives sell upAssetco director adds to holdingTim Martin, chairman of pub group JD Wetherspoon (JDW), sold 1,361,000 shares at 739p each for a total value of more than £10 million on 29 July.As a result of the deal, Martin's voting rights now comprise of 30,382,253 shares, equivalent to 24.6% of the issued share capital of the company

Investor excitement surrounding weight-loss drugs has arguably been as great if not greater than that seen for everything AI (artificial intelligence) in the last two years.Market leaders Novo Nordisk (NOVO-B:CPH) and Eli Lilly (LLY:NYSE), makers of Wegovy and Zepbound respectively, have seen their share prices soar as investors seemingly extrapolate their initial success years into the future.Ben

Stocks in Europe took a hit on Thursday, with eyes on US economic data due out this afternoon and on Friday.The FTSE 100 index traded down 59.21 points, or 0.7%, at 8,094.48. The FTSE 250 was down 224.81 points, 1.1%, at 20,726.03, while the AIM All-Share fell 7.50 points, 1.0%, at 769.14.The Cboe UK 100 was down 0.7% at 807.67, the Cboe UK 250 dropped 1.2% to 18,129.36, and the Cboe Small Compani

European equities nursed heavy losses at the open on Thursday, as investors weighed a mixed bag of earnings and hefty losses in US markets.Still, the FTSE 100 index traded down 60.56 points, or 0.7%, at 8,093.13. The FTSE 250 was down 201.65 points, 1.0%, at 20,749.19, while the AIM All-Share fell 5.35 points, 0.7%, at 771.29.The Cboe UK 100 was down 0.7% at 807.72, the Cboe UK 250 dropped 1.1% to

Porsche AG (P911:ETR) €69.98Market cap: €31.3 billionAt first glance it may look like an odd time to pitch Porsche AG (P911:ETR) to readers, but we have seen many times that fundamentally good companies can be picked up on the relative cheap during testing times, and that's the scenario we now believe is in front of investors.The shares trade under the name of Dr ING F Porsche AG, which

The FTSE 100 finished lower at the close on Wednesday, as tech earnings weighed on equities across the pond, despite figures showing a strong result for UK business activity in July.The FTSE 100 index closed down 13.68 points, 0.2%, at 8,153.69. The FTSE 250 ended down 140.65 points, 0.7%, at 20,950.84, and the AIM All-Share closed down 3.53 points, 0.5%, at 776.64.The Cboe UK 100 ended down 0.1%

London's stocks were shaky going into Wednesday afternoon, despite data showing a pick up in UK private sector growth.Amongst individual stocks, easyJet was flying after it said it is on track to deliver another 'record-breaking summer'.The FTSE 100 index traded 13.83 points lower, or 0.2%, at 8,154.04. The FTSE 250 was down 58.02 points, 0.3%, at 21,033.47, while the AIM All-Share was down 1.34 p

Miners dragged the FTSE 100 into the red on Tuesday, as stocks in London finished the session lower at the close.The FTSE 100 index closed down 31.41 points, 0.4%, at 8,167.37. The FTSE 250 ended down 47.19 points, 0.2%, at 21,091.49, and the AIM All-Share closed down 3.07 points, 0.4%, at 780.17.The Cboe UK 100 ended down 0.5% at 814.73, the Cboe UK 250 closed down 0.5% at 18,388.59, and the Cboe

THIS IS AN ADVERTISING FEATURE Marketing material.A lot has been said about the concentration in the US markets, but investors in European markets have also been focused on a handful of companies. These 'Granolas' may be more diversified than the technology-focused Magnificent Seven ? and not as expensive ? but the focus on them suggests investors remain nervous about branching out. However, there

After a positive first-quarter trading update which helped power the shares to a 16% gain year-to-date all eyes are on Unilever's (ULVR) first-half update on 25 July.In the three months to March, the group reported 4.4% underlying sales growth with a positive performance in all five divisions led by Beauty and Wellbeing where growth topped 7% during the quarter.Moreover, the firm's 'Power Brands',

EU approves drug to treat chronic lung diseaseFirst targeted treatment for COPDDrug expected to generate €20 billion in salesFrench drug maker Sanofi (SAN:EPA) has received European regulatory approval for Dupixent, its asthma and skin drug to treat patients with chronic lung disease.Dupixent is the first-ever targeted therapy for COPD (chronic obstructive pulmonary disease), known as 'smoker

AstraZeneca's cancer drug combo gets green lightApplications being reviewed in several countriesCovid-19 prevention drug gets fast-trackedA combination of AstraZeneca's (AZN) cancer treatments Imfinzi and Lynparza has been recommended for approval in the EU by the CHMP (Committee for Medicinal Products for Human Use) for patients with certain advanced or recurrent endometrial cancer.In addition, I

US approval for endometrial cancer drugLeads to 58% improvement in survival ratesImfinzi generated sales of $4.2 billionPharmaceutical giant AstraZeneca (AZN) said it has received US regulatory approval for its cancer drug Imfinzi to treat patients with advanced or recurrent endometrial cancer.The approval was based on results from a late-stage trial which showed Imfinzi plus carboplatin and pacli

CEO's $56 billion package biggest in corporate historyHuge backing thought to have come from army of small investorsStock has put up yearly returns of 66.5% since 2019Corporate pay packets can be a tetchy topic with investors but not those backing Tesla (TSLA:NASDAQ). Thousands of shareholders voted to back Elon Musk's enormous $56 billion compensation deal, the biggest in corporate history.This w

The space sector is gaining traction with investors again amid increased activity among names spanning US aircraft maker Boeing (BA:NYSE), defence giant BAE Systems (BA.) and Elon Musk-backed SpaceX.On 5 June Boeing launched its long-delayed astronaut capsule Starliner towards the International Space Station with two Nasa astronauts on board.Butch Wilmore and Suni Williams ? the astronauts in ques

THIS IS AN ADVERTISING FEATURE Imran Sattar, Portfolio Manager of Edinburgh Investment TrustWe like to diversify the Edinburgh Investment Trust within the 40 to 50 holdings in the portfolio by both companies and economic exposure. The portfolio currently is well diversified across stocks and sectors with a range of different economic characteristics.The most significant positions in the portfoli